Theriva Biologics, Inc. - 8-K Filing
Theriva Biologics reports Q3 2026 results with $8.5M cash on hand and completes SYN-004 asset sale to Biossil Labs. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits (d) Exhibits)